Objective: To add to the limited data on the prevalence, clinical characteristics, and treatment of bipolar disorder (BD) among immigrants.
C anadian census data reveals that over 5.4 million residents of Canada were born outside the country. 1 The proportion of immigrants in Canada has risen for decades, and currently stands at 18% of the Canadian population. Numerous studies in Canada and elsewhere have examined different aspects of the mental health needs and treatments among immigrant groups [2] [3] [4] [5] [6] ; nonetheless, limited data are available on immigrants with BD. The estimated lifetime prevalence of BD is in the range of 1% to 2% 7, 8 ; therefore, there are likely up to 100 000 immigrants with BD in Canada. Despite this large number, little is known nationally or even internationally about the prevalence, characteristics, and treatment of BD among immigrants. Such data are needed to better understand and provide the mental health care needs of this population.
Epidemiologic studies have suggested a disparity in rates of mania among specific ethnic groups, [9] [10] [11] [12] [13] [14] [15] [16] but immigrant status has generally not been examined in these analyses. The limited clinical data that are available on the effect of immigrant status on presence of BD has yielded inconclusive results, with one report of manic subjects being significantly more likely to be foreign-born than subjects with schizophrenia in a small sample of inpatients from McLean Hospital. 17 Another report found no differences in immigrant status between outpatients with BD, compared with unipolar depression, in the National Institute of Mental Health Collaborative Study. 18 Previous reports from Canada, 19, 20 the United States, 4, 21, 22 and outside North America 3 have found that immigrants appear to be less likely to receive mental health treatment for various mental health conditions. 6, [23] [24] [25] [26] [27] We are not aware of any such reports specifically examining treatment use among immigrants with BD. With the growing appreciation of the tremendous public health burden associated with BD, 7, 9 this lack of information on treatment patterns among immigrants to Canada represents a gap in our understanding of this population.
There are inherent challenges in establishing the proper diagnosis and treatment of BD in the community. 28, 29 This is evidenced by the fact that most patients with BD were initially misdiagnosed with other Axis I or II disorders. 28, 30 When the addition of language barriers and heightened stigma among immigrant communities is considered, 3, 31 there may be even lower rates of identification and treatment use for BD.
The CCHS 1.2 is a large, epidemiologic survey that identified a representative sample of respondents with BD. 32 Data from CCHS 1.2 provides an opportunity to examine possible differences in lifetime prevalence rates and characteristics of BD among immigrants in Canada, as well as determining rates and type of mental health treatment use. An earlier report from our group using this dataset suggested an independent effect of immigrant status on decreased likelihood of any broadly defined mental health treatment contact among BD subjects; however, the specific providers and types of treatment have not previously been examined. 33 Our aim is to more comprehensively examine: the effect of immigrant status on the lifetime prevalence rate and characteristics of BD, and to describe specific differences in treatment for BD between immigrant and nonimmigrant subjects.
Methods

Survey
Data was obtained from the CCHS 1.2. 34 Full methodological details of this survey have been previously published. 32 35 The survey was administered by well-trained lay interviewers using computer-assisted methods. Data on sociodemographics, psychiatric diagnoses, illness history, mental health treatment contacts, and past 12-month medication use were collected. Immigrant status was defined by country of birth other than Canada. Details of immigration, including country of origin, age at time of immigration, and number of years since arrival in Canada were obtained. The examination of data on specific country of origin contravened privacy guidelines established, a priori, by Statistics Canada that restrict access to cell sizes of less than 5 subjects; therefore, we completed analysis using region of origin (Asia, Europe, Other) rather than country of origin. Similarly, the role of ethnicity, independent of immigrant status, could not be fully determined because of the sample size and privacy guideline restrictions.
Participants were interviewed in person at their place of residence whenever possible (86% of subjects); the remaining interviews were conducted by telephone. To mitigate the impact of language barrier, interviews were conducted in English, French, Chinese, or Punjabi (as required) by interviewers with proven competency in each of the languages. An official translation of key terms was used for interviews conducted in Chinese or Punjabi. Use of other languages was not possible, owing to the lack of an official translation of terms to standardize the surveys content.
BD Diagnosis
Subjects meeting study criteria for a current or lifetime CCHS 1.2-defined manic episode were considered to have the diagnosis of BD. Study criteria for a manic episode differed from DSM-IV criteria only in duration of symptoms, with several days or longer required in CCHS 1.2, compared with "at least 1 week" 35, p 362 in DSM-IV-TR. All remaining criteria had to be simultaneously met, including: elevated or irritable mood; 3 or more additional DSM-IV-defined manic symptoms; significant functional impairment; and manic symptoms could not be due to medications, drugs, alcohol, or physical causes. The interview did not include criteria needed to accurately differentiate subjects with BD type I, II, not otherwise specified, or non-DSM-IV-based definitions of BD.
Sociodemographic Variables
Age, sex, ethnicity, language fluency, marital status (married, formerly married, or never married), highest level of education, current employment, and income adequacy were determined. Income adequacy is a refined measure of economic status that accounts for number of household residents, with low income adequacy defined by a household income of less than $15 000 for 1 to 2 residents; less than $20 000 for 3 to 4 residents; or less than $30 000 for 5 or more residents.
Clinical Variables
Major depressive episodes were defined according to DSM-IV criteria. The age of illness onset was defined as the age of first manic or depressive episode, whichever occurred first. The presence of manic and depressive episodes during the past 12 months and number of lifetime manic and depressive episodes were also determined. To avoid a highly skewed distribution, the number of lifetime manic and depressive episodes was capped at 50 each. A lifetime history of comorbid anxiety disorder was established by the presence of a DSM-IV diagnosis of panic disorder, agoraphobia, or social phobia. Other anxiety disorders were not assessed in the interview. A past 12-month history of a comorbid substance use disorder was defined as heavy alcohol or illicit drug use associated with 1 or more DSM-IV substance abuse or dependence criteria. Psychological distress in the previous month was measured using the Kessler Psychological Distress Scale (K10), a 10-item scale with higher scores reflecting greater distress. 37
Treatment Use
Lifetime contact with any treatment services was determined with the question: "During your lifetime, have you ever seen, or talked on the telephone, to any of the following professionals about your emotions, mental health or use of alcohol or drugs?" followed by the interviewer reading categories of treatment providers. These included: psychiatrist, primary care physician, psychologist, psychotherapist (social worker or counsellor), and religious or spiritual adviser. More than one type of treatment provider could be selected. For this analysis, we defined lifetime contact with a mental health professional as contact with a psychiatrist, psychologist, or psychotherapist.
Respondents were also asked about use of any medical or psychotropic medications as well as use of specific classes of psychotropic medications during the previous 12 months. Mood stabilizer, antidepressant, antipsychotic, and sedative and (or) hypnotic categories were each probed and common examples of medications in each class were given.
Statistical Analysis CCHS 1.2 used a multistage, stratified cluster design to select eligible households. To take into account the effects of this complex survey design, all results were bootstrapped using a set of replicate weights supplied by Statistics Canada. All results (except sample sizes) are reported as weighted estimates. Weighted lifetime prevalence of BD and each of the sociodemographic, clinical, and treatment use variables were compared between immigrant and nonimmigrant subjects with BD using 2-sided t tests for continuous variables and Pearson chi-square tests for categorical variables. Correlates of lifetime contact with a mental health professional and 12-month psychotropic medication use were both determined using logistic regression. The regression models included several sociodemographic and clinical variables. To avoid the necessity of substantial listwise deletions, a missing variable indicator was included for income.
Data for our study were obtained from the CCHS 1.2 Master File maintained at the Statistics Canada Research Data Centre, Toronto, Canada. The analysis was conducted using Stata 9.0. 38 This study was approved by the research ethics board at Sunnybrook Health Sciences Centre, University of Toronto.
Results
The weighted lifetime prevalence rate of CCHS 1.2-defined BD was significantly lower among immigrant (1.50%, 95% CI 1.05% to 1.94%), compared with nonimmigrant, subjects (2.27%, 95% CI 2.04% to 2.51%) (P = 0.01). The sociodemographic, clinical characteristics, and immigration details of immigrants and nonimmigrants with BD are shown in Table 1 . There were significant ethnic differences between the groups, with immigrants more likely than nonimmigrants to be Asian (44.5% and 1.6%) and less likely to be Caucasian (43.5% and 91.0%) (P < 0.001). There was also a nonsignificant trend toward fewer immigrants having low income (7.5% and 15.4%, P = 0.07) and fewer immigrants having a comorbid substance use disorder (15.4% and 29.1%, P = 0.07). There were no significant differences in age, sex, or other sociodemographic variables, as well as no significant differences in age of illness onset, number of lifetime manic or depressive episodes, percentage of subjects with a manic or depressive episode in the past year, lifetime comorbid anxiety, and overall psychological distress. Table 2 outlines the rates of contact with specific treatment providers and medication use among immigrants and nonimmigrants with BD. Immigrants had significantly lower rates of any lifetime mental health treatment contact (47.3% and 71.2%, P < 0.001), and this difference was present for each treatment provider group, including physicians, other health professionals, and religious advisers. Table 3 shows the results of the logistic regression used to determine the independent correlates of contact with a mental health professional. Immigrant status was associated with a significantly lower likelihood of contact (OR 0.25, 95% CI 0.13 to 0.50, P < 0.001), whereas increasing age (OR 1.04, per year, 95% CI 1.02 to 1.06, P < 0.001) and presence of a comorbid anxiety disorder (OR 1.65, 95% CI 1.11 to 2.44, P < 0.001) were each significantly associated with a greater likelihood of contact.
When comparing medication use between immigrants and nonimmigrants with BD, there was no significant difference in the percentage of participants who used one or more prescribed medication for any medical or psychiatric reasons. In contrast, psychotropic medications were significantly less frequently used by immigrants with BD, compared with nonimmigrants with BD (24.5% and 41.0%, P = 0.02). This difference was also present specifically for antidepressant and mood stabilizer classes. Logistic regression was completed to determine the independent correlates of any past 12-month psychotropic medication use (Table 4 ). When controlling for other factors, there was a trend toward immigrant status associated with lower likelihood of psychotropic medication use, but this did not reach statistical significance (OR 0.49, 95% CI 0.24 to 1.01, P = 0.05).
Discussion
A main finding of this report is the significantly lower weighted lifetime prevalence rate of BD among immigrants, compared with nonimmigrants, in Canada. Based on the lifetime prevalence rate of 1.50% (95% CI 1.05% to 1.94%), there are likely to be in the range of 56 000 to 104 000 immigrants with BD in Canada. While we are not aware of data from any other large epidemiologic surveys on the prevalence of BD among immigrants, lower rates of depression, anxiety, and substance use disorders among immigrant groups has been previously identified in Canada and elsewhere. 3, 5, 6, 20, 22 Lower rates of various medical and psychiatric conditions among immigrants have most often been attributed to the healthy immigrant effect, that is, the presence of better health among immigrants. 5, 39 These differences can be understood as being related to self-selection for immigration as well as government policies that favour immigration among healthier people. 40 Our finding of a lower prevalence rate of BD lends further support to the presence of a healthy immigrant effect for mental health disorders; however, prospective longitudinal data are needed to better understand the multiple factors associated with this difference. 5, 39, 40 Additional factors are also likely at play, because mean age at time of immigration (18.4 years) was more than 5 years younger than the mean age of onset of BD in this study (23.8 years), and 64.6% of immigrants developed their BD after immigrating. Given the heritability of BD, 41, 42 it is possible that parents of BD respondents may have carried a greater personal or family burden of mental illness, resulting in lower likelihood of acceptance for immigration. Further, our findings may reflect use of DSM-IV-defined manic symptoms to establish the diagnosis of BD. The cultural applicability of DSM-IV criteria among immigrants groups has not been established and may potentially lead to underrecognition of this condition. 43 Ethnicity may also play an important role in the reported lower prevalence rates of BD among immigrant subjects. In our sample, immigrants were most commonly of Asian background, and data suggest that in North America, Asian immigrant populations in particular have lower rates of overall mental illness than the general population or other immigrant groups. 4, 6, 44, 45 Although this may be a result of the low baseline prevalence rates of BD reported in several Asian countries, 46, 47 these data on lower rates of mental illness and treatment use among ethnic groups inside or outside North America must be interpreted with caution. Several additional factors should be considered, including limitations of using DSM-IV criteria that are not specific to ethnic groups, 48 the role of cultural and religious beliefs surrounding mental health and psychiatric treatments, [49] [50] [51] and examining ethnic categories as homogeneous groups. 52 A more comprehensive determination of the interaction between immigrant status, ethnicity, and these other factors is needed 53 ; however, this was beyond the scope of our paper owing to limits of quantitative data, and sample size restrictions that did not allow for an accurate determination of differences in lifetime prevalence of BD within ethnic groups.
A comparison of sociodemographic and illness characteristics revealed few differences between immigrant and nonimmigrant subjects with BD. These similarities suggest 37 with a range of 0 to 40 (higher score reflects greater distress) n/a = not applicable an equivalent need for mental health services; however, levels of treatment use were much lower for immigrant participants. Immigrants were about one-half as likely to have had contact with a psychiatrist (20.8% and 42.3%), and were significantly less likely to have contact with any mental health professional, even when controlling for other factors in the analysis. These results mirror earlier Canadian data that reported immigrant groups having lower rates of overall mental health service use, 21, 24 as well as contact with specialty physicians for other illnesses. 53 Taken as a whole, these findings support the need for further studies to explore the patient and health system factors that contribute to this lower degree of treatment use seen among immigrants with BD. Service barriers appear to be heightened in the presence of ethnic and cultural discordance between patient and health care providers, 54 as well as leading to lower rates of correct diagnoses and treatments being established. 55 This underscores the need to improve cultural competency training for physicians and the dissemination of psychoeducation that is specific to the needs of immigrant communities. [56] [57] [58] Language disparity may also be an important aspect to consider, as a language barrier between health care providers and recipients has been shown to result in underuse of health care services and lower quality of care for various conditions, [59] [60] [61] [62] [63] including BD. 64 We found no significant differences between immigrants and nonimmigrants in general fluency in either English or French, and respondents who were not fluent in either language could be interviewed in the 2 most common nonofficial languages. However, it is quite possible that more subtle cultural and linguistic differences between patients and health care providers may impede full understanding of health information, resulting in lower treatment use. [61] [62] [63] Results of our study should be interpreted in the context of several limitations, some of which are intrinsic to large epidemiologic datasets. These include cross-sectional assessments, lack of information on people who declined to participate, and absence of collateral information from family or clinical records to determine accuracy of responses. Further, the absence of data on prevalence rates of BD among immigrants in other epidemiologic surveys limits the possibility of comparisons with other countries; therefore, the generalizability of this result beyond the immigrant population of Canada is not known. Immigration policies differ from country to country, and it is conceivable that Canada's immigration policies exerted an influence on the prevalence and characteristics of BD in immigrants. Finally, subanalyses of factors such as ethnicity, specific waves of immigration, or region of origin were also limited by privacy restrictions over data analysis involving small numbers of subjects. Despite this limitation, the large number of subjects in CCHS 1.2, compared with other national epidemiologic surveys, allowed for a rare examination of the impact of immigrant status within a low prevalence illness such as BD. 
Conclusions
Results from this epidemiologic sample suggest that immigrants have a significantly lower lifetime prevalence rate of BD than nonimmigrants in Canada. Clinical characteristics of BD did not differ significantly by immigrant status; nonetheless, immigrants were significantly less likely to have contact with mental health professionals. Further studies are needed to better elucidate the multiple sources of these differences. Résultats : Le taux de prévalence de durée de vie du TB défini par l'ESCC 1.2 était significativement plus faible chez les sujets immigrants, comparés aux sujets non immigrants (1,50 % et 2,27 %, P = 0,01). Il y avait peu de différences sociodémographiques ou cliniques, et pourtant les immigrants souffrant du TB étaient significativement moins susceptibles de déclarer tout contact dans leur vie avec les professionnels de la santé mentale (RC = 0,25, IC 95 % 0,13 à 0,50, P < 0,001). L'utilisation de psychotrope dans l'année précédente était en apparance le seuil de plus faible chez les immigrants souffrant du TB (24,5 % et 41,0 %); cependant, cela n'atteignait pas signification statistique lorsque d'autres facteurs étaient contrôlés (RC = 0,49, IC 95 % 0,24 à 1,01, P = 0,05).
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